Janssen Leverages Wearable Technology To Reimagine Clinical Trial Design

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the launch of the next evolution of digital clinical trial design with CHIEF-HF, the first-ever completely decentralized, mobile, indication-seeking clinical study. To accelerate the study and fast-track results, all contact with participants will be done virtually, with no in-person clinical visits required. Drawing on previous experience, the company is utilizing smart technology and wearable devices to more quickly and efficiently gather and analyze real-world evidence to assess the effectiveness of canagliflozin in adults with heart failure (HF), with or without type 2 diabetes. Through a . . .